Q-linea can reach its main market faster than planned
Q-linea AB (publ) (OMX: QLINEA), today announced that the company's first product ASTar™ is expected to launch on the company’s main market, the U.S., three to four months than earlier communicated to take advantage of strong market interest and positive feedback from the US Food and Drug Administration, the FDA. The European launch is thus postponed to the same extent.In Q-linea's discussions with potential sales partners, increasing emphasis has been placed on the US market. Against this background, and because of the positive feedback Q-linea received from the US Food and Drug